Last reviewed · How we verify
transdermal nicotine patches
At a glance
| Generic name | transdermal nicotine patches |
|---|---|
| Sponsor | National Institute on Drug Abuse (NIDA) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment (PHASE4)
- STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking (NA)
- Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings (NA)
- Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV (NA)
- Varenicline and Combined NRT for Smoking Cessation (PHASE4)
- Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension (PHASE2)
- Depressed Mood Improvement Through Nicotine Dosing 3 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- transdermal nicotine patches CI brief — competitive landscape report
- transdermal nicotine patches updates RSS · CI watch RSS
- National Institute on Drug Abuse (NIDA) portfolio CI